FDA warned Reckitt/Mead Johnson over Cronobacter contamination and inadequate process controls at two powdered infant formula plants.
What happened
FDA inspected two powdered infant formula plants: Zeeland, Michigan from February 7, 2023, through February 23, 2023, and Wanamingo, Minnesota from November 28, 2022, through January 9, 2023. At Zeeland, FDA found a finished Prosobee batch positive for Cronobacter sakazakii, environmental positives in high and critical hygiene zones, water leaks, and excessive powder spillage around fillers. At Wanamingo, FDA found the firm did not independently investigate a customer-reported finished product positive for C. sakazakii and had environmental Cronobacter positives with incomplete root cause follow-up.
What FDA found
FDA found the company did not have a complete system of process controls to prevent microorganisms from contaminating infant formula or the processing environment.
21 C.F.R. § 106.55(a)At Zeeland, a finished batch of Enfamil Prosobee Simply Plant-Based Infant Formula tested positive for Cronobacter sakazakii, and FDA found the root cause review incomplete and the release of later batches not adequately supported.
21 C.F.R. § 106.55(a)At Zeeland, Cronobacter was found in high and critical hygiene zones, and some environmental test reports that were outside limits lacked required root cause information or corrective action documentation.
21 C.F.R. § 106.55(a)At Zeeland, FDA saw water leaks and dripping water in high hygiene zones and found deviation reports missing required mitigation and corrective-action details.
21 C.F.R. § 106.55(a)At Wanamingo, after a customer reported finished product positive for Cronobacter sakazakii, the company did not run its own root cause investigation or evaluate other affected products, and FDA found environmental Cronobacter positives with incomplete follow-up.
21 C.F.R. § 106.55(a)At Zeeland, FDA found vacuum fillers were not adequately designed, causing excessive powder spillage around the filling line in a critical hygiene zone.
21 C.F.R. § 106.30
What FDA wants
FDA tells the company to take prompt action to correct the violations and says failure may lead to legal action such as seizure or injunction. FDA will assess the adequacy of the corrective actions during its next inspection; no specific response deadline is stated.
Who should pay attention
- infant formula manufacturers and contract packers
- brands that buy powdered infant formula or base powder
- quality teams running Cronobacter environmental monitoring
This is a summary. Read the original letter on fda.gov.